🔗 Share this article

While the United States continues making historic changes to its vaccination recommendations, an unexpected name appears somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who initially gained attention by expressing skepticism about COVID-19 shots during the global health crisis and has concentrated on alleged fatalities after COVID-19 immunization in her recent time at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Immunization Schedule

Public health authorities were set to unveil sweeping revisions to the childhood vaccine schedule recently, synchronizing the US with Denmark’s vaccine program, according to reports – a significant shift that would place the US out of alignment with much of the international standard with insufficient data for benefit. The planned update has been postponed until the next year.

Rather than the top vaccines chief, Tracy Beth Høeg is set to present at the gathering. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth appointee to lead the office this year.

A New Direction at the Agency

The acting appointment could signify a tighter collaboration between the pharmaceutical and biologics centers as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it suggests a greater focus upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for ending specific childhood shot schedules in the US in order to be more in line with the Danish model, a society with comprehensive healthcare and a number of inhabitants approximately the size of Wisconsin’s.

To date comments, she has kept her attention on vaccines – usually the domain of Dr. Prasad, director of the FDA’s CBER – instead of pharmaceutical oversight.

Questions Over Background

Høeg has no obvious track record in medication creation, oversight or administrative roles, which has been typical for past directors of the CBER. She has served at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for leading the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in running a sizeable institution. She is not an expert in pharmaceutical oversight.”

Former directors of the center would “be deeply familiar with laws and regulations and the underlying principles of drug development”, commented Dr. Janet Woodcock. “Clearly, she has not acquired the type of experience that previous people who headed CBER have had.”

This division has an enormous workload at the FDA, she pointed out.

“Everybody just focuses on the novel medication approvals, but the off-patent medication office approves numerous generic medications. There’s a biosimilars division, OTC medication office and other areas, and all of those need to be managed,” Dr. Woodcock said. “The thing you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a major administrative element to the role, which manages in excess of 5,000 personnel. “It’s a enormous administrative position, if you execute it properly,” she added.

Official Statement and Disputed Policies

Regarding questions about Dr. Høeg's qualifications and whether this assignment signifies increased cooperation among regulatory chiefs on immunizations, a spokesperson said that the “inquiries stem from inaccurate assumptions”.

“This background matches the responsibilities of her role,” the representative said, noting the period Høeg spent guiding the agency head on “drug safety and regulatory science, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a disputed rapid drug-approval program that reportedly worried her preceding directors. “By what process are these medications being selected for this voucher program? Who is making the choices?” Howard questioned. “There is a lot of confidentiality going on at the FDA right now.”

In general, he remarked, “the FDA looks to be trending towards less stringent oversight of all drugs, aside from immunizations.”

Documented Track Record on Vaccines

With immunizations, Høeg has a more documented, if concerning, history, Howard have noted. She authored a analysis using non-validated public submissions to determine the frequency of myocarditis after COVID-19 vaccination. She consulted for the Florida chief medical officer Joseph Ladapo, who was said to have changed statistics to suggest COVID-19 vaccines are pose a greater threat than they are.

Part of her “desired changes” for the new government included changing guidelines for recently developed shots and ending “unnecessary” immunizations, she said following the vote on a podcast. At the agency, Dr. Høeg has reportedly suggested excluding young men from getting Covid vaccines.

“She is an thorough ideologue who starts off with her conclusions and works backwards to fit the science in a highly disingenuous, dishonest fashion,” Dr. Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg joined fellow dissenters, {like|